Citations

Showing 10 of 108083 citations.

Chronic Intermittent Ethanol Exposure Alters Behavioral Flexibility in Aged Rats Compared to Adult Rats and Modifies Protein and Protein Pathways Related to Alzheimer’s Disease
Ho, Ada Man‐Choi , Peyton, Mina P. , Scaletty, Samantha , Trapp, Sarah , Schreiber, Areonna , Choi, Doo‐Sup , Matthews, Douglas B. , Scaletty, Samantha J, Choi, Doo-Sup , Matthews, Douglas B , Ho, Ada M-C , Madden, Benjamin

Mayo Clinic

ACS Omega | December 7, 2022 | Volume: 7 | Issue: 50 | Pages: 46260-46276

10.1021/acsomega.2c04528 | PMID 36570296 Get It

Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas
Fuentes, Harry E , Patel, Sandip Pravin , Mardiros, Armen, Han, Xu , Ng, Eric Wai-Choi , Go, William Y., Wong, Deborah Jean Lee, Sunwoo, John B. , Welch, John S. , Fuentes, Harry E , Xu, Han , Ng, Eric W , Kirtane, Kedar , John, Maie A. St.

Mayo Clinic

Journal of Clinical Medicine | December 7, 2022 | Volume: 11 | Issue: 24 | Pages: 7259

10.3390/jcm11247259 | PMID 36555876 Get It

Head and neck squamous cell cancers (HNSCCs) represent a diverse group of tumors emerging within different mucosal surfaces of the oral cavity, nasopharynx, oropharynx, larynx, and hypopharynx. HNSCCs share common clinical risk factors and genomic features, including smoking, alcohol, age, male sex, aneuploidy, and TP53 mutations. Viral initiating and contributing events are increasingly recognized in HNSCCs. While both Epstein–Barr Virus (EBV) and human papilloma virus (HPV) are observed, EBV is more frequently associated with nasopharyngeal cancers whereas HPV is associated with oropharyngeal cancers. HNSCCs are associated with high tumor mutational burden and loss of tumor suppressor gene function, especially in TP53 and X-linked genes. Multiple lines of evidence suggest that HNSCCs are subject to immunologic surveillance and immune-induced evolutionary pressure that correlate with negative clinical outcomes. This review will discuss genomic mechanisms related to immune-mediated pressures and propose prognostic and therapeutic implications of detectable immune escape mechanisms that drive tumorigenesis and disease progression.
Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations
Sampson, Maureen , Wolska, Anna , Cole, Justine , Zubirán, Rafael , Otvos, James D. , Meeusen, Jeff W., Jaffe, Allan S. , Remaley, Alan T. , Donato, Leslie J. , Meeusen, Jeffrey W. , Jaffe, Allan S.

Mayo Clinic

Biomedicines | December 7, 2022 | Volume: 10 | Issue: 12 | Pages: 3156

10.3390/biomedicines10123156 | PMID 36551912 Get It

New more effective lipid-lowering therapies have made it important to accurately determine Low-density lipoprotein-cholesterol (LDL-C) at both high and low levels. LDL-C was measured by the β-quantification reference method (BQ) (N = 40,346) and compared to Friedewald (F-LDL-C), Martin (M-LDL-C), extended Martin (eM-LDL-C) and Sampson (S-LDL-C) equations by regression analysis, error-grid analysis, and concordance with the BQ method for classification into different LDL-C treatment intervals. For triglycerides (TG) < 175 mg/dL, the four LDL-C equations yielded similarly accurate results, but for TG between 175 and 800 mg/dL, the S-LDL-C equation when compared to the BQ method had a lower mean absolute difference (mg/dL) (MAD = 10.66) than F-LDL-C (MAD = 13.09), M-LDL-C (MAD = 13.16) or eM-LDL-C (MAD = 12.70) equations. By error-grid analysis, the S-LDL-C equation for TG > 400 mg/dL not only had the least analytical errors but also the lowest frequency of clinically relevant errors at the low (<70 mg/dL) and high (>190 mg/dL) LDL-C cut-points (S-LDL-C: 13.5%, F-LDL-C: 23.0%, M-LDL-C: 20.5%) and eM-LDL-C: 20.0%) equations. The S-LDL-C equation also had the best overall concordance to the BQ reference method for classifying patients into different LDL-C treatment intervals. The S-LDL-C equation is both more analytically accurate than alternative equations and results in less clinically relevant errors at high and low LDL-C levels.
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection
Jacobson, Jeffrey M. , Zahrieh, David M. , Strand, Carrie , Cruz‐Correa, Marcia , Roberts, Lewis R. , Mandrekar, Sumithra J. , Rodriguez, Luz M. , Boyer, Jean , Marrero, Idania , Kraynyak, Kimberly A. , Morrow, Matthew P. , Sylvester, Albert J. , Pawlicki, Jan M. , Gillespie, Elisabeth, Barranco, Eduardo , Network, for the Cancer Prevention, Zahrieh, David , Strand, Carrie A , Pungpapong, Surakit , Roberts, Lewis R , Mandrekar, Sumithra J , RODRIGUEZ, LUZ MARIA , Boyer, Jean , Marrero, Idania , Kraynyak, Kimberly A , Morrow, Matthew P , Sylvester, Albert J , Pawlicki, Jan M , Gillespie, Elisabeth , Barranco, Eduardo , Richmond, Ellen S. , Umar, Asad , Weiner, David B , Limburg, Paul J , Cruz-Correa, Marcia , Pungpapong, Surakit , Limburg, Paul J. , Network, for the Cancer Prevention

Mayo Clinic

Cancer Prevention Research | December 6, 2022 | Volume: 16 | Issue: 3 | Pages: 163-173

10.1158/1940-6207.capr-22-0217 | PMID 36534786 Get It

Abstract Chronic hepatitis C can lead to cirrhosis and hepatocellular carcinoma. We studied the safety and immunogenicity of a novel therapeutic hepatitis C virus (HCV) genotype 1a/1b consensus DNA vaccine, INO-8000, encoding HCV NS3, NS4A, NS4B, and NS5A proteins alone or co-administered with DNA-encoding IL12 (INO-9012), a human cytokine that stimulates cellular immune function, in individuals with chronic hepatitis C. This was a phase I, multisite dose-escalation trial with an expansion cohort evaluating doses of 0, 0.3, 1.0, and 3.0 mg of INO-9012 (IL12 DNA) as an addition to 6.0 mg of (INO-8000; HCV DNA vaccine). Vaccines were administered by intramuscular injection followed by electroporation at study entry and at weeks 4, 12, and 24. HCV-specific CD4+ and CD8+ T-cell immune responses were measured by IFNγ ELISpot and flow cytometry–based assays. Transient, mild-to-moderate injection site reactions unrelated to IL12 DNA dose were common. Increases in HCV-specific IFNγ production occurred in 15/20 (75%) participants. Increases in the frequency of HCV-specific CD4+ and CD8+ T cells occurred at all dose levels, with the greatest increases seen at 1.0 mg of INO-9012. HCV-specific CD8+ and CD4+ T-cell activities increased in 16/18 (89%) and 14/17 (82%) participants with available data, respectively. The vaccine regimen was safe and induced HCV-specific CD4+ and CD8+ cellular immune responses of modest magnitude in most HCV-infected participants. The addition of 1.0 mg of IL12 DNA provided the best enhancement of immune responses. The vaccine regimen had little effect on controlling HCV viremia. Prevention Relevance: The administration of IL12 DNA along with a hepatitis C viral antigen DNA vaccine enhanced the HCV-specific immune responses induced by the vaccine in individuals with chronic hepatitis C, an important cause of hepatocellular carcinoma. IL12 could be an effective adjuvant in vaccines targeting HCV and other oncogenic viruses.
Association of circulating markers with cognitive decline after radiation therapy for brain metastasis
Huntoon, Kristin , Anderson, S. Keith , Twohy, Erin , Dooley, Katharine , Jiang, Wen , An, Yi , Qie, Yaqing, Ross, Owen A. , Cerhan, Jane H. , Whitton, Anthony , Greenspoon, Jeffrey , Ashman, Jonathan B. , Bahary, Jean-Paul , Urbanic, James J., Farace, Elana, Khuntia, Deepak , Laack, Nadia N., Brown, Paul D. , Jiang, Wen , Ross, Owen A , Dooley, Katharine , Ballman, Karla V. , Li, Jing , Roemeling, Christina A. Von , Parney, Ian F. , Hadjipanayis, Costas G. , Roberge, David , Kim, Betty Y.S.

Mayo Clinic

Neuro-Oncology | December 6, 2022 | Volume: 25 | Issue: 6 | Pages: 1123-1131

10.1093/neuonc/noac262 | PMID 36472389 Get It

AbstractBackgroundA recent phase III trial (NCT01372774) comparing use of stereotactic radiosurgery [SRS] versus whole-brain radiation therapy [WBRT] after surgical resection of a single brain metastasis revealed that declines in cognitive function were more common with WBRT than with SRS. A secondary endpoint in that trial, and the primary objective in this secondary analysis, was to identify baseline biomarkers associated with cognitive impairment after either form of radiotherapy for brain metastasis. Here we report our findings on APOE genotype and serum levels of associated proteins and their association with radiation-induced neurocognitive decline.MethodsIn this retrospective analysis of prospectively collected samples from a completed randomized clinical trial, patients provided blood samples every 3 months that were tested by genotyping and enzyme-linked immunosorbent assay, and results were analyzed in association with cognitive impairment.ResultsThe APOE genotype was not associated with neurocognitive impairment at 3 months. However, low serum levels of ApoJ, ApoE, or ApoA protein (all P &lt; .01) and higher amyloid beta (Aβ 1–42) levels (P = .048) at baseline indicated a greater likelihood of neurocognitive decline at 3 months after SRS, whereas lower ApoJ levels were associated with decline after WBRT (P = .014).ConclusionsPatients with these pretreatment serum markers should be counseled about radiation-related neurocognitive decline.
Chordal Preservation Mitral Valve Replacement for Delayed MitraClip Failure
Greason, Kevin L. , Spittell, Peter C., Wright, R. Scott

Mayo Clinic

Texas Heart Institute Journal | December 6, 2022 | Volume: 49 | Issue: 6 | Pages: No page available

10.14503/thij-21-7599 | PMID 36472917 Get It

Mitral valve replacement may be indicated in delayed MitraClip (Abbott) failure. Although it would be best to preserve the chordal apparatus during surgical mitral valve replacement, this has not been reported for delayed MitraClip failure, probably because there is almost always impressive inflammation around the MitraClip, which has likely precluded previous attempts at chordal preservation. A successful surgical chordal preservation mitral valve replacement in delayed MitraClip failure is reported here.
Incidentally Discovered Cor Triatriatum Sinistrum Anomaly During Heart Transplant
Ahmed, Magdy M. El‐Sayed , Makey, Ian A. , Thomas, Mathew , Jacob, Samuel , Landolfo, Kevin , Thomas, Mathew , Landolfo, Kevin P, Pham, Si M. , Thomas, Mathew

Mayo Clinic

Texas Heart Institute Journal | December 6, 2022 | Volume: 49 | Issue: 6 | Pages: No page available

10.14503/thij-20-7453 | PMID 36472916 Get It

Is Contrast-induced Acute Kidney Injury Still a Risk in Pediatric Patients?
McDonald, Jennifer S.

Mayo Clinic

Radiology | December 6, 2022 | Volume: 307 | Issue: 1 | Pages: No page available

10.1148/radiol.222775 | PMID 36472540 Get It

Perfusion from Diffusion: Yet Another Take on Mismatch
Kallmes, David F. , Rabinstein, Alejandro A. , Rabinstein, Alejandro A

Mayo Clinic

Radiology | December 6, 2022 | Volume: 307 | Issue: 1 | Pages: No page available

10.1148/radiol.222743 | PMID 36472541 Get It

In Vitro Activity of a Hypochlorous Acid-Generating Electrochemical Bandage against Yeast Biofilms
Kletzer, Joseph , Raval, Yash S. , Mohamed, Abdelrhman , Mandrekar, Jayawant N. , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Patel, Robin , Mohamed, A , Raval, Yash S. , Beyenal, Haluk

Mayo Clinic

Antimicrobial Agents and Chemotherapy | December 6, 2022 | Volume: 67 | Issue: 1 | Pages: No page available

10.1128/aac.01166-22 | PMID 36472429 Get It

The antibiofilm activity of a hypochlorous acid (HOCl)-producing electrochemical bandage (e-bandage) was assessed against 14 yeast isolates in vitro . The evaluated e-bandage was polarized at +1.5 V Ag/AgCl to allow continuous production of HOCl.